Fructose-induced Intestinal de Novo Lipogenesis

Completed

• Conditions: Obesity
• Interventions: Other: fat+protein meal; Other: Fat + protein + 13C fructose meal; Other: Fat+protein+13C fructose+glucose meal; Other: 13C Fat + whey protein; Other: 13C Fat + whey protein + glucose+ glucose meal

• Registration Number: NCT01792089
• Lead Sponsor: University of Lausanne

Brief Summary

8 healthy volunteers, 8 pre-bypass obese subjects, 8 subjects between 12-18 months post-bypass, and 8 subjects matched to the post-bypass patients will be studied in two sub-studies Sub-study 1) after ingestion of two or three different of the following test-meals: A)cream and whey protein B)cream, whey protein and fructose + 13C6 fructose C)test meal with cream, whey protein, fructose and glucose + 13C6 fructose Their intestinal de novo lipogenesis will be estimated by measuring 13C-palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in blood Sub-study 2) after ingestion of two or three different of the following test-meals: A)cream labelled with 13C6 palmitic acid and whey protein B))cream labelled with 13C6 palmitic acid, whey protein, fructose and glucose

Their intestinal de novo lipogenesis will be estimated by measuring 13C-palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in blood in sub-study 1

Their exogenous lipid absorption kinetics will be assessed by measuring 13C palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in sub-study 2

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02
• Study First Submitted: 2013-02-12
• Study First Submitted QC: 2013-02-13
• Study First Posted: 2013-02-15
• Primary Completion: 2016-12
• Study Completion: 2016-12
• Status Verified: 2019-03
• Last Update Submitted: 2019-03-22
• Last Update Posted: 2019-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• age 18-50 years
• sex male or female
• less than 2 kg body weight change over the past 3 months subjects

Exclusion Criteria

• antidiabetic and hypolipemic drugs
• alcohol consumption >20g/day
• severe eating disorders
• severe psychological problems
• vegetarian diet or other specific diet
• consumption of illicit substances
• pregnancy
• weight gain or weight loss > 1 kg in the last 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
non-obese healthy subjects	13C Fat + whey protein	subjects with BMI\<25 and no known disease
non-obese healthy subjects	13C Fat + whey protein + glucose+ glucose meal	subjects with BMI\<25 and no known disease
post-gastric bypass	fat+protein meal	post-obese subjects 12-48 months after Roux-en-Y gastric bypass
matched control subjects	Fat + protein + 13C fructose meal	Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
post-gastric bypass	13C Fat + whey protein + glucose+ glucose meal	post-obese subjects 12-48 months after Roux-en-Y gastric bypass
non-obese healthy subjects	fat+protein meal	subjects with BMI\<25 and no known disease
post-gastric bypass	Fat + protein + 13C fructose meal	post-obese subjects 12-48 months after Roux-en-Y gastric bypass
matched control subjects	13C Fat + whey protein + glucose+ glucose meal	Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
non-obese healthy subjects	Fat + protein + 13C fructose meal	subjects with BMI\<25 and no known disease
non-obese healthy subjects	Fat+protein+13C fructose+glucose meal	subjects with BMI\<25 and no known disease
matched control subjects	fat+protein meal	Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects

Primary Outcome Measures

Name	Time	Method
Intestinal de novo lipogenesis (sub-study 1)	0-8-hour post-prandial	Measurement of total TG and 13C palmitate in chylomicrons: The sf \>20 fraction of post-prandial blood samples will be prepared, and non-chylomicrons, apoB100-containing lipoprotein will be removes by immuno-affinity chromatography using a specific anti-apoB100 antibody
Postprandial exogenous, labelled palmitate concentration (sub-study 2)	0-8-hour post-prandial	Measurement of total TG and 13C palmitate in chylomicrons of sf \>20 fraction of post-prandial blood samples will be prepared,

Secondary Outcome Measures

Name	Time	Method
post-prandial triglyceride profile (sub-studies 1 and 2	0-8 hour post-prandial	Triglyceride will be measured in the chylomicron, VLDL, LDL and HDL fractions of post-prandial blood samples

Trial Locations

Locations (1)

Centre Hospitalier Universitaire Vaudois; 🇨🇭 Lausanne, VD, Switzerland